Polish Atrial Fibrillation (POL-AF) Registry
POL-AF
1 other identifier
observational
4,000
1 country
1
Brief Summary
Evaluation of clinical characteristics and pharmacotherapy of hospitalized Polish patients with atrial fibrillation (AF).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 6, 2019
CompletedFirst Submitted
Initial submission to the registry
May 13, 2020
CompletedFirst Posted
Study publicly available on registry
June 5, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedJuly 29, 2020
July 1, 2020
1.5 years
May 13, 2020
July 27, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assessment of the frequency of VKAs vs NOACs prescription in AF patients treatment of with OACs.
Compared data will include: frequency of VKAs vs NOACs prescriptions.
Through the study completion, an average of 2 months.
Secondary Outcomes (2)
Assessment of the frequency of appropriate/inappropriate OACs prescription in AF patients.
Through the study completion, an average of 2 months.
Number of patients with AF treated with apixaban, dabigatran and rivaroxaban with high thromboembolism risk according to CHA2DS2-VASc (heart failure, hypertension, age, diabetes mellitus, stroke/TIA/thromboembolism, vascular disease and sex) score.
Through the study completion, an average of 2 months.
Study Arms (2)
Patients with AF treated with VKA
Patients with AF treated with NOAC
Interventions
Eligibility Criteria
All patients with AF hospitalized in a participating center during study period.
You may qualify if:
- \- patients with AF hospitalized in a participating center during study period
You may not qualify if:
- hospitalisation for atrial fibrillation ablation
- death during hospitalization
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jan Kochanowski Universitylead
- Medical University of Warsawcollaborator
Study Sites (1)
Iwona Gorczyca
Kielce, 25-525, Poland
Related Publications (1)
Uzieblo-Zyczkowska B, Krzesinski P, Maciorowska M, Gorczyca I, Jelonek O, Wojcik M, Blaszczyk R, Kaplon-Cieslicka A, Gawalko M, Tokarek T, Rajtar-Salwa R, Bil J, Wojewodzki M, Szpotowicz A, Krzciuk M, Bednarski J, Bakula-Ostalska E, Tomaszuk-Kazberuk A, Szyszkowska A, Welnicki M, Mamcarz A, Wozakowska-Kaplon B. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, including compliance with current guidelines-data from the POLish Atrial Fibrillation (POL-AF) Registry. Cardiovasc Diagn Ther. 2021 Feb;11(1):14-27. doi: 10.21037/cdt-20-839.
PMID: 33708474DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Iwona Gorczyca, Md,PhD
Collegium Medicum, Jan Kochanowski University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD, Principal Investigator
Study Record Dates
First Submitted
May 13, 2020
First Posted
June 5, 2020
Study Start
January 6, 2019
Primary Completion
June 30, 2020
Study Completion
December 31, 2020
Last Updated
July 29, 2020
Record last verified: 2020-07